DePuy Orthopaedics Newswire

Comprehensive Real-Time News Feed for DePuy Orthopaedics.

Results 1 - 20 of 554 in DePuy Orthopaedics

  1. Xarelto Is the Least Costly Novel Anticoagulant, AIS Researchers FindRead the original story

    22 hrs ago | PRWeb

    Xarelto's low price translates into the lowest out-of-pocket costs to members, according to analysis conducted by the editors of Atlantic Information Services's new online resource Rx Benefit Design Data. Xarelto, a novel oral anticoagulant manufactured by BayerHealthcare AG and Johnson & Johnson division Janssen Pharmaceuticals, Inc., has the lowest retail cost when compared with two of its major competitors, according a random sampling conducted by the editors of Atlantic Information Services, Inc.'s Rx Benefit Design Data , a new online subscription database with detailed data, news and insight on prescription drug benefit parameters of health plans.

    Comment?

  2. Chipotle Shares Already Pricing In 5,000 LocationsRead the original story w/Photo

    Yesterday | Seeking Alpha

    I think shares are already pricing in 5,000 locations, and that is beyond saturation; I don't see a bullish scenario. Shareholders of burrito giant Chipotle have certainly enjoyed the past two years.

    Comment?

  3. Keep safe with proper medication storageRead the original story

    Monday | Fitchburg Star

    It was not until years later that I understood the reason for this ad campaign; serving a bigger role in the community by teaching people the importance of cleaning their medicine cabinets. Those ads haven't been around for 30 years, but the message of throwing away old medication is still relevant today.

    Comment?

  4. Jim Cramer Answers Twitter (TWTR) Questions on Johnson & Johnson, Alcoa, Mobileye, and FacebookRead the original story w/Photo

    Monday | TheStreet.com

    Cramer says he thinks Mobileye was a speculative stock with some interesting technologies, but he would rather play the interesting technologies in Harman Industries STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

    Comment?

  5. Johnson & Johnson: 'Slightly Overvalued' Is No Reason To SellRead the original story w/Photo

    Friday Jan 23 | Seeking Alpha

    In a recent article another contributor offered the following headline: "Johnson & Johnson Is Slightly Overvalued, Time To Sell." As you might have guessed from my article's title, I would contend that this is a dangerous way to think about the investing world.

    Comment?

  6. What They're Saying: Damian CollinsRead the original story

    Thursday Jan 22 | Soccer America

    "Fifa is a toxic brand. I think that's why companies who care about their reputation don't want to be associated with [it]."

    Comment?

  7. Investors Sold Johnson & Johnson For All the Wrong ReasonsRead the original story w/Photo

    Friday Jan 23 | The Motley Fool

    To put it mildly, Wall Street and investors weren't thrilled with the outcome, and its shares fell $2.75, or 2.6%. I know that may not sound like much, but when you're talking about one of the market's stalwart stocks, and also one of its least volatile, a move of this magnitude is likely to gain some attention.

    Comment?

  8. 3 FIFA sponsors won't renew for 2018 World Cup in RussiaRead the original story w/Photo

    Friday Jan 23 | NewsOK.com

    Three second-tier World Cup sponsors opting not to renew for the 2018 tournament in Russia was normal in sports business, FIFA insisted on Friday. Castrol, Continental and Johnson & Johnson all let their World Cup commercial deals expire in December amid widespread allegations of corruption implicating FIFA executive committee members.

    Comment?

  9. Johnson & Johnson's Strong Momentum Will ContinueRead the original story w/Photo

    Thursday Jan 22 | GuruFocus.com

    With a strong product portfolio, Johnson & Johnson entered the new fiscal year on a strong note. The company released strong results, with a solid improvement in earnings.

    Comment?

  10. Judge to decide if Boston Scientific should pay $7.2B to Johnson & JohnsonRead the original story w/Photo

    Thursday Jan 22 | Business Journal

    The decision as to whether Boston Scientific should pay competitor Johnson & Johnson $7.2 billion - nearly all of the Marlborough company's revenues last year - is now in the hands of a federal judge.

    Comment?

  11. WSJ: Dollar's Rise Produces Pain for US CompaniesRead the original story w/Photo

    Wednesday Jan 21 | News Max

    The dollar's surge to multi-year highs against a range of major currencies in recent weeks is good news for inflation, as it makes our imports cheaper in dollars. And it's good news for Americans traveling overseas, as our dollars are now worth more foreign currency.

    Comment?

  12. Johnson & Johnson Release: Dr. Paul Janssen Award For Biomedical...Read the original story

    Tuesday Jan 20 | BioSpace

    Award for Biomedical Research today opens its 2015 call for nominations. This prestigious award recognizes individuals whose scientific research has made, or has the potential to make, significant contributions toward the improvement of human health.

    Comment?

  13. DePuy ASR Hip Implant Lawsuits Purporting Painful Revision Surgery...Read the original story w/Photo

    Wednesday Jan 21 | PRWeb

    ... District of Ohio where DePuy ASR lawsuits have been consolidated for pretrial proceedings (In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation - MDL 2197) Wright & Schulte LLC is currently representing numerous clients in ...

    Comment?

  14. Argentina Rails Against Government over Tampon ShortageRead the original story w/Photo

    Tuesday Jan 20 | Breitbart.com

    The government of Argentina is facing heavy criticism for its heavy-handed control of the economy in light of a recent tampon shortage. The Argentine government announced last week that it had finally defeated the tampon shortage.

    Comment?

  15. San Joaquin County settles in lawsuit against Johnson & Johnson and NeutrogenaRead the original story

    Tuesday Jan 20 | RecordNET

    Last week, on Jan. 13, the District Attorney's Offices of Shasta, Fresno, San Joaquin and Yolo counties reached a settlement in a consumer protection lawsuit against Johnson & Johnson and Neutrogena. The counties brought forward product packaging violations in over-the-counter sales of health and beauty products by the two companies, according to an announcement from Shasta County.

    Comment?

  16. Steve Beaman: Oil & Gasoline Prices Won't Rebound SoonRead the original story w/Photo

    Tuesday Jan 20 | News Max

    Oil and gasoline prices have dropped to 5 -year lows in recent days, and Steve Beaman, chairman of the Society to Advance Financial Education, told Newsmax TV that he doesn't see them coming back soon. U.S. crude oil traded at $46.49 a barrel Tuesday afternoon, and national regular gas prices averaged $2.05 a gallon.

    Comment?

  17. Johnson & Johnson: 31 Consecutive EPS Increases & CountingRead the original story w/Photo

    Tuesday Jan 20 | Seeking Alpha

    Johnson & Johnson is the most consistent business I have analyzed . The company has the lowest stock price volatility in the Dividend Aristocrats Index.

    Comment?

  18. Johnson & Johnson tops 4Q earnings expectationsRead the original story w/Photo

    Tuesday Jan 20 | Salt Lake Tribune

    Trenton, N.J. a Health care giant Johnson & Johnson's fourth-quarter profit dropped 28 percent as lower sales overseas, mainly because of unfavorable currency exchange rates, dragged down revenue for its consumer and medical device businesses. The maker of Tylenol, prescription drugs and joint replacements beat analysts' forecasts for adjusted net income but fell short of predictions for revenue.

    Comment?

  19. J&J Faces Headwinds in 2015Read the original story

    Tuesday Jan 20 | Morningstar

    Johnson & Johnson reported fourth-quarter results largely in line with our expectations, and we don't expect any changes to our $99 fair value estimate or wide moat rating. While the pharmaceutical segment continues to post robust growth, up 14% year over year in the quarter, we expect increased generic and branded competition and continued sluggish sales from consumer and medical devices to lead to overall 2015 sales growth of 1%, excluding foreign exchange rate changes.

    Comment?

  20. Johnson & Johnson Reports 2014 Fourth-Quarter And Full-Year ResultsRead the original story

    Monday Jan 19 | BioSpace

    Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

    Comment?